Century Therapeutics shares jump 13.48% after-hours after Zacks upgrades to Strong Buy on improved earnings estimates.

Century Therapeutics (NASDAQ:IPSC) surged 13.48% in after-hours trading following a Zacks Rank upgrade to "Strong Buy," reflecting improved earnings estimate revisions. The upgrade, driven by a 31.9% increase in analysts’ consensus estimates for fiscal year 2025, signals growing confidence in the company’s earnings trajectory. The Zacks system, which correlates earnings revisions with near-term price movements, positions the stock in the top 5% of its universe, likely spurring buying pressure. While older news included mixed analyst ratings and operational updates, the Zacks upgrade’s focus on earnings momentum aligns directly with the post-market rally, overshadowing prior bearish sentiment from downgrades or weak Q2 results.